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Abstract    
Ion channels represent a large and growing family of target proteins regulated by 
gasotransmitters such as nitric oxide, carbon monoxide and, as described more recently, 
hydrogen sulfide. Indeed, many of the biological actions of these gases can be accounted 
for by their ability to modulate ion channel activity. Here, we report recent evidence that H2S 
is a modulator of low voltage-activated T-type Ca2+ channels, and discriminates between 
the different subtypes of T-type Ca2+ channel in that it selectively modulates Cav3.2, whilst 
Cav3.1 and Cav3.3 are unaffected. At high concentrations, H2S augments Cav3.2 currents, 
an observation which has led to the suggestion that H2S exerts its pro-nociceptive effects 
via this channel, since Cav3.2 plays a central role in sensory nerve excitability. However, at 
more physiological concentrations, H2S is seen to inhibit Cav3.2. This inhibitory action 
requires the presence of the redox-sensitive, extracellular region of the channel which is 
responsible for tonic metal ion binding, and which particularly distinguishes this channel 
isoform from Cav3.1 and 3.3. Further studies indicate that H2S may act in a novel manner 
to alter channel activity by potentiating the zinc sensitivity  / affinity of this binding site. This 
review discusses the different reports of H2S modulation of T-type Ca2+ channels, and how 
such varying effects may impact on nociception, given the role of this channel in sensory 
activity. This subject remains controversial, and future studies are required before the impact 
of T-type Ca2+ channel modulation by H2S might be exploited as a novel approach to pain 
management. 
 
 
Abbreviations:   
CAT, cysteine aminotransferase; CBS, cystathionine β synthase; CO, carbon monoxide; 
CSE, cystathionine γ lyase; DRG neuron, dorsal root ganglion neuron; DTT, dithiothreitol; 
H2S, hydrogen sulphide; HEK293 cells, human embryonic kidney cells; RMP, resting 
membrane potential; LTMR, low threshold mechanoreceptor; MCO, metal-catalysed 
oxidation; 3-MST, 3-mercaptopyruvate sulfurtransferase; NaHS, sodium hydrosulfide 
hydrate; NMDAR, N-methyl-D-aspartate receptor; NO, nitric oxide; TPEN, N,N,N',N'-
tetrakis(2-pyridylmethyl)ethane-1,2-diamine; TRP, Transient receptor potential channels.  
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Introduction 
Ion channel activity is central to a vast and diverse array of cellular functions in both excitable 
and non-excitable cell types. They control, for example, gene expression, apoptosis, 
proliferation, contractility, fluid transport, exocytosis, excitability and action potential 
propagation. It is therefore unsurprising that the number of genes encoding ion channel 
proteins (either the pore-forming proteins or auxiliary subunits) runs into the hundreds. This 
diversity is further increased by splice variation and also the fact that subunits of different 
channel types can form functional channels by combining with other (albeit related) subunits 
to form heteromeric complexes. Of the many functions regulated by ion channels one of the 
most important is the control of [Ca2+]i as this ion is a ubiquitous intracellular signalling 
molecule that mediates many of the ways in which channels influence the above-mentioned 
fundamental cellular functions (Berridge et al., 2003;Clapham, 2007). Here, we discuss 
recently discovered new modes of regulation of one specific class of Ca2+ channel, the 
voltage-gated T-type Ca2+ channel.   
Tailoring ion channel activity to serve specific and often co-ordinated roles requires not only 
the availability of multiple channel types, but also that they can be dynamically regulated. 
This can occur by a plethora of means; for example by coupling to specific G-proteins and 
via numerous post-translational modifications including phosphorylation, ubiquitination, 
sumoylation, nitrosylation, sulfhydration and S-acylation (Rajan et al., 2005;Lipscombe et 
al., 2013;Gonzalez et al., 2009;Mustafa et al., 2011;Shipston, 2014). Such modifications can 
regulate ion channel trafficking and membrane insertion, as well as ongoing activity. In 
recent years, it has become apparent that ion channels are also modulated by endogenously 
generated, biologically active gases, often termed gasotransmitters; such as nitric oxide, 
carbon monoxide and hydrogen sulfide (NO, CO and H2S respectively). The roles of these 
gases, especially NO, in diverse physiological and pathological settings have in many 
instances been long-established, but the concept that they represent a new class of ion 
channel regulators is currently emerging (Wilkinson & Kemp, 2011;Peers et al., 2012;Peers 
et al., 2014). In this article, we focus on H2S specifically as a modulator of voltage-gated T-
type Ca2+ channels.  
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T-type Ca2+ channels 
When first described at the single channel level, this class of voltage-gated Ca2+ channel 
was named “T-type” since members had a relatively tiny conductance and gave rise to 
transient currents (Nowycky et al., 1985). These channels are also distinguished from other 
voltage-gated Ca2+ channels by their rapid activation, slow deactivation and very negative 
activation thresholds, as low as -60mV or even below (Carbone & Lux, 1984;Perez-Reyes, 
2003;Iftinca & Zamponi, 2009). Example currents are shown in Fig. 1A, and a typical current-
voltage relationship is presented in Fig. 1B. Owing to this low threshold for activation, they 
also may display a significant window current (i.e. display tonic activity; Fig. 1C, arrowed) at 
potentials close to the resting membrane potential (RMP), and so can provide a sustained 
route for Ca2+ entry into resting cells (exemplified in Fig. 1D) and also contribute to setting 
the RMP (Perez-Reyes, 2003). Three genes, CACNA1G, CACNA1H and CACNA1I give rise 
to pore-forming α-subunits of T-type Ca2+ channels, which are nowadays referred to 
respectively as Cav3.1-3.3 (Catterall et al., 2005), with Cav3.3 showing relatively slower 
activation and inactivation kinetics than Cav3.1 or Cav3.2 (Fig. 1A). Heterologous 
expression of individual Cav3 α-subunits gives rise to currents which closely resemble native 
T-type Ca2+ currents, suggesting that auxiliary subunits are not required for assembly of 
functional Ca2+ channels, although other channel properties and trafficking may indeed be 
affected by the auxiliary subunits (Dolphin et al., 1999).  
T-type Ca2+ channels are widely distributed, but their physiological functions have 
sometimes proved difficult to resolve. This is certainly true in vascular smooth muscle cells 
(VSMCs), where Cav3.1 and Cav3.2 are expressed. Numerous attempts have failed to 
record “classic” T-type Ca2+ channel activity in VSMCs (reviewed in (Kuo et al., 2011;Kuo et 
al., 2014)). Recent studies suggest this is because VSMCs primarily express T-type Ca2+ 
channel splice variants which do not activate at the low voltages normally associated with 
T-type Ca2+ channels. Instead, they activate over more depolarised voltage ranges as are 
observed for L-type Ca2+ channels. Splice variation accounting for these differences occurs 
in Cav3.1 (and similarly in Cav3.2) primarily around exons 25 and 26, corresponding to the 
intracellular linker region between domains III and IV (Chemin et al., 2001;Emerick et al., 
2006;Latour et al., 2004). Four variants have been identified, termed 25a, 25b, 25bc and 
25ac, with variant 25bc predominating in both the juvenile and mature systemic vasculature. 
These variants all contribute to vasomotor tone (Kuo et al., 2011;Kuo et al., 2014), and may 
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also have a pacemaker role, controlling slow Ca2+ waves and contractile oscillations (Cribbs, 
2006).  
Despite continued uncertainty around the physiological roles of T-type Ca2+ channels in the 
vasculature, it appears that in several vascular diseases the influence of T-type Ca2+ 
channels, particularly Cav3.1, becomes more prominent. Their increased expression and 
activity appears to be instrumental in pathological vascular remodelling in both the systemic 
and pulmonary circulation, providing a route for Ca2+ entry which is required for proliferation 
(Tzeng et al., 2012;Chevalier et al., 2014). Interestingly, numerous cancers also rely on the 
expression of T-type Ca2+ channels for proliferation, and hence tumour growth 
(Dziegielewska et al., 2014). These findings suggest that they represent a promising 
therapeutic target in the treatment of various cancers and cardiovascular diseases.   
In the nervous system, T-type Ca2+ channels serve better defined roles. Thus, for example, 
in thalamic and corticothalamic neurones T-type Ca2+ channels are responsible for 
pacemaker activity and low threshold spikes (Huguenard & Prince, 1994), as illustrated in 
the cartoon of Fig. 1E. They contribute to “rebound” bursts of spikes following a 
hyperpolarizing postsynaptic potential. Indeed, evidence suggests that all three isoforms of 
T-type Ca2+ channels can contribute to this excitability (Kim et al., 2001;Joksovic et al., 
2006;Lee et al., 2014). In the peripheral nervous system, T-type Ca2+ channels are 
prominent in somatosensory fibres including small, capsaicin-sensitive (presumed 
nociceptive) dorsal root ganglion (DRG) neurons (Jevtovic-Todorovic & Todorovic, 
2006;Nelson et al., 2006;Rose et al., 2013) as well as in two distinct populations of low-
threshold mechanoreceptors (LTMRs), Aδ- and C-LTMRs, innervating skin hair follicles 
(Francois et al., 2015). Cav3.2 is the dominant form in DRG and may even be the exclusive 
form in some mechanosensitive neurons (Shin et al., 2003). They can control burst firing in 
DRG neurons (White et al., 1989) and so strongly influence excitability (Nelson et al., 
2005;Nelson et al., 2007a), implying they are of central importance to nociception since 
stimulus intensity correlates with burst frequency. Indeed, the role of T-type Ca2+ channels 
in pain is well recognised and has been covered in depth in several recent reviews (Bourinet 
et al., 2014;Todorovic & Jevtovic-Todorovic, 2014;Francois et al., 2014;Waxman & 
Zamponi, 2014;Zamponi et al., 2015). Thus, conditional genetic deletion (Francois et al., 
2015), or downregulation of Cav3.2 in DRG using intrathecal injection of antisense 
oligonucleotides (Bourinet et al., 2005;Messinger et al., 2009) produced strong anti-
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nociceptive effects in rodent pain models of neuropathic and inflammatory pain. Conversely, 
T-type Ca2+ currents are often increased in pathological conditions associated with chronic 
pain, such as diabetic neuropathy (Jagodic et al., 2007;Messinger et al., 2009), peripheral 
nerve injury or inflammation (Jagodic et al., 2008;Garcia-Caballero et al., 2014;Marger et 
al., 2011). Both the enhancement of channel trafficking (Orestes et al., 2013;Weiss et al., 
2013) and enhanced deubiquitination (Garcia-Caballero et al., 2014) were reported as 
underlying mechanisms for the latter phenomenon.  
It is not entirely clear how exactly T-type Ca2+ channels participate in the nociceptive 
transmission. Cav3.2 channel expression has been detected in different compartments of 
afferent fibers including peripheral nociceptive terminals and axons of skin afferents (Rose 
et al., 2013;Francois et al., 2015), nodes of Ranvier of Aδ fibers (Francois et al., 2015) as 
well as in the presynaptic terminals of nociceptive fibers in the spinal cord ((Jacus et al., 
2012) however, cf. Francois et al., 2015). Therefore, multiple mechanisms (or their 
combinations) are conceivable, including setting the threshold for action potential generation 
(at the nerve terminals) and propagation (at the nodes of thinly myelinated fibres), supporting 
burst firing, or indeed promoting synaptic activity at the central terminals of afferent fibres. 
Finally, since T-type Ca2+ channels are expressed in skin terminals of low threshold 
mechanoreceptors, including D-hair cells (Coste et al., 2007;Francois et al., 2015), a more 
direct role of T-type Ca2+ channels in mechanotransduction also cannot be excluded.     
In accordance with strong evidence for the physiological role of T-type Ca2+ channels in 
pain, recent data clearly demonstrated that pharmacological inhibition of T-type Ca2+ 
channel activity produces strong anti-nociceptive effects in various rodent pain models 
(Todorovic et al., 2001;Todorovic et al., 2002;Todorovic et al., 2004;Latham et al., 2009). 
Together with N-type Ca2+ channels, T-type Ca2+ channels are clinically validated drug 
targets for pain (Bourinet et al., 2014). Accordingly, intense search is currently underway for 
novel pharmacological tools targeting T-type Ca2+ channel activity. These need to be more 
selective than widely used blockers such as mibefradil which, despite its ability to inhibit T-
type Ca2+ channels, is not highly selective (Bezprozvanny & Tsien, 1995). This new 
generation of more selective T-type inhibitors (e.g. TTA-A2, TTA-P2, KYS-05090S) shows  
promising analgesic properties in animal models of pain (Choe et al., 2011;Francois et al., 
2013). Another novel, selective and orally bioavailable T-type Ca2+ channel blocker, Z944, 
which showed analgesic activity in animal models of inflammatory and neuropathic pain, is 
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currently being tested in clinical trials as a first-in-class novel oral analgesic (Lee, 2014). 
Moreover, Zamponi’s lab has recently developed small molecule modulators that prevent 
deubiquitination of the Cav3.2 channels by the deubiquitinase USP5, which in turn, can 
prevent channel upregulation in chronic pain conditions (Gadotti et al., 2015). 
A redox- and Zn2+-sensitive ‘module’ within the Cav3.2 subunit  
Studies in both native DRG neurons and recombinant expression systems have revealed a 
regulatory site within Cav3.2 which confers high sensitivity to redox agents, distinguishing it 
functionally from both Cav3.1 and Cav3.3. Thus, for example, T-type Ca2+ currents recorded 
in native nociceptive neurones and recombinant Cav3.2 currents are enhanced by reducing 
agents (dithiothreitol (DTT) or L-cysteine) and inhibited by the oxidising agent 5,5’-dithio-
bis(2-nitrobenzoic acid) (DTNB) (Nelson et al., 2007a). Sensitivity to these agents was 
exploited in order to demonstrate the importance of Cav3.2 in nociception: hindpaw 
injections of DTT or L-cysteine induces thermal and mechanical hyperalgesia (Todorovic et 
al., 2001), and such effects are prevented with the Ca2+ channel inhibitor mibefradil; 
furthermore, analgesic effects are observed with DTNB (Todorovic et al., 2001). Such 
findings were confirmed in a subpopulation of nociceptive neurons expressing high levels of 
Cav3 channels (Nelson et al., 2005). An important breakthrough in the field was achieved 
by the joint work of Perez-Reyes’ and Lee’s groups which allowed the characterization of 
specific Cav3.2 residues involved in the metal-induced inhibition of the Ca2+ channel. The 
redox-sensitive module is located extracellularly, involving interaction of the extracellular 
IS1-IS2 linker region with the IS3-IS4 linker region (Kang et al., 2010), the latter region 
containing a histidine residue (H191) which is key to conferring high redox sensitivity to this 
channel. Intriguingly, the same H191 residue that is involved in modulation of T-type Ca2+ 
channel activity by redox mechanisms also mediates T-type Ca2+ channel inhibition by low 
(sub-micromolar) concentrations of extracellular Zn2+ (Kang et al., 2006;Kang et al., 2010). 
The full Zn2+ binding site also includes residues that precede H191, namely D189 and G190, 
as well as the negatively charged residues at the outer portion of the IS2 segment (Kang et 
al., 2010). It is, as yet, unclear how exactly the redox- and Zn2+-mediated modulatory 
pathways converge at the same site but one hypothesis suggests that H191 may represent 
a general binding site for transition metals (e.g. iron, copper, zinc) and can be subject to 
oxidation via a metal-catalysed oxidation (MCO) reaction (Stadtman, 2001;Nelson et al., 
2007a). It is conceivable therefore that either binding of metal (e.g. Zn2+) or Zn2+-
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independent MCO of H191 may result in a similar inhibition of channel activity. An alternative 
hypothesis is that oxidative modification (possibly but not necessarily at H191) can increase 
the effect of metal binding either by increasing the affinity at the binding site or by enhancing 
coupling efficiency between the metal binding and channel inhibition. In such a scenario, 
oxidative modification could result in sensitization of the channel to Zn2+ (and potentially 
other transition metals) making the channel sensitive to ambient concentrations in biological 
fluids. Total Zn2+ concentration in human plasma is reported to be within the range of 5-20 
µM (Moran et al., 2012). Although it is likely that the free [Zn2+] is considerably lower, it is 
still quite plausible that the extracellular free [Zn2+] can reach the nanomolar range at which 
changes in Zn2+ affinity/sensitivity of Cav3.2 subunits may result in noticeable changes in 
channel activity. While the exact mechanism of regulation of Cav3.2 activity via the H191-
containing regulatory site remains to be elucidated, it is clear that redox modulation is 
involved in the action on the T-type Ca2+ channels of some pharmacological agents and 
physiological signalling cascades including nitrous oxide (Orestes et al., 2011), CO and 
thioredoxin (Boycott et al., 2013), as well as GABAB receptors (Huang et al., 2015).   
H2S as a gasotransmitter  
H2S is regarded as the third ‘gasotransmitter’, since it is an endogenous, enzymatically-
generated, biologically active gas. Emerging evidence indicates that it has widespread 
physiological and pathophysiological importance throughout the body (Li et al., 2011). 
Unsurprisingly, therefore, it has received increasing interest as a potential therapeutic target 
over the past decade or so, as was the case previously for both NO and CO (Leffler et al., 
2006;Moore et al., 2003;Szabo, 2007). H2S is generated primarily by the action of two widely 
distributed enzymes, cystathionine γ lyase (CSE) and cystathionine β synthetase (CBS; Fig. 
2). Both synthesise the gas from L-cysteine. More recently, the mitochondrially-located 3-
mercaptopyruvate sulfurtransferase (3-MST) has also been found to generate H2S in both 
the brain and vasculature (Fig. 2). 3-MST generates H2S from 3-mercaptopyruvate which is 
itself generated by cysteine aminotransferase (CAT; (Kimura, 2010)). Red blood cells can 
generate H2S non-enzymatically from inorganic polysulfides, a finding which has prompted 
the idea that H2S may mediate the beneficial vascular effects of dietary garlic (Benavides et 
al., 2007). H2S is also known to be liberated in a redox- or pH-sensitive manner from sulfur 
‘stores’; i.e. sulfur bound to proteins in mitochondria or the cytosol (Kimura, 2010). 
Differential distribution of H2S-generating enzymes results in a predomination of CBS in the 
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central nervous system, along with 3-MST (Leffler et al., 2006); whereas CSE is dominant 
peripherally, generating the majority of H2S elsewhere in the body, including the vasculature. 
More recently, H2S has been shown to be generated from D-cysteine (Fig. 2), particularly in 
the cerebellum and kidney, via a novel pathway involving 3-MST and D-amino acid oxidase 
(Shibuya et al., 2013).   
H2S as a regulator of ion channels 
Ion channels (specifically NMDA receptors; (Abe & Kimura, 1996)) were amongst the first 
family of cellular proteins recognized as being molecular targets of H2S. Since then, reports 
of ion channel regulation by H2S have grown rapidly (Peers et al., 2012;Kuksis & Ferguson, 
2015;Zhang et al., 2015), as suggested in Fig. 2. It is clear that modulation by H2S is not 
confined to any particular class of ion channels (such as voltage- or ligand-gated channels) 
or to channels which are selective for specific ions (e.g. K+, Na+ , Ca2+ or Cl-)(Zhang et al., 
2015). H2S is also known to interfere with a number of intracellular signalling pathways 
(Wang, 2012), and it is via these pathways that H2S, in some cases, modifies ion channel 
activity. In other cases, direct post-translational modification accounts for its effects. The 
best studied of these is the vascular smooth muscle ATP-sensitive K+ channel (KATP 
channel), which becomes more active when sulfhydrated (i.e. when –SH groups within 
cysteine residues are altered to –SSH groups). This direct process (also known as 
persulfidation; see (Paul & Snyder, 2015)) contributes to vasorelaxation and thereby 
protects against hypertension (Paul & Snyder, 2012;Mustafa et al., 2011).  
The list of ion channels regulated by H2S is long and continues to grow. However, some 
areas of contention have arisen along the way. Thus, for example, inhibition by H2S of the 
high-conductance, Ca2+-sensitive K+ channel has been described in detail (Telezhkin et al., 
2010), yet others report activation of this channel by H2S (Sitdikova et al., 2010;Jackson-
Weaver et al., 2013). Similarly, inhibition of L-type Ca2+ channels in cardiac myocytes (Sun 
et al., 2008;Avanzato et al., 2014) contrasts with the observed augmentation of L-type Ca2+ 
channel activity reported in astrocytes (Nagai et al., 2004). Such discrepancies may have 
simple explanations, but these need to be identified if H2S modulation of ion channels is to 
be exploited therapeutically. The remainder of this review is focussed on the known pro-
algesic effects of H2S and considers the recent, conflicting data concerning the role of T-
type Ca2+ channels in this process.  
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H2S as a regulator of Cav3.2 
Our group has recently reported an inhibitory effect of micromolar concentrations of H2S on 
recombinant and native T-type Ca2+ channels in sensory neurons (Elies et al., 2014).  
Among Cav3 subunits, this effect was selective to Cav3.2 while Cav3.1 and Cav3.3 were 
insensitive to H2S. In agreement with the predominant expression of Cav3.2 subunits in 
DRG neurons, H2S also strongly inhibited endogenous low-voltage activated (LVA) currents 
in these neurons. Interestingly, the same extracellular histidine residue H191, which is 
necessary for Cav3.2 modulation by Zn2+ and redox agents, was also found critical for the 
effect of H2S. Thus, an H191Q mutation in Cav3.2 abolished channel sensitivity to H2S and 
the analogous reciprocal mutation in Cav3.1 (Q172H) conferred sensitivity to H2S on this 
subunit (Elies et al., 2014). It is not entirely clear exactly how redox/Zn2+-binding of Cav3.2 
is implicated in this H2S-mediated effect but one theory is that H2S may increase channel 
sensitivity to extracellular Zn2+. Indeed, chelation of ambient Zn2+ with TPEN (N,N,N',N'-
tetrakis(2-pyridylmethyl)ethane-1,2-diamine) fully reversed the H2S-mediated T-type Ca2+ 
channel inhibition. Moreover, pre-treatment with TPEN abolished H2S-mediated inhibition 
when H2S was applied in the continued presence of TPEN. However, subsequent washing 
out of TPEN in the presence of H2S allowed the inhibition to commence (Elies et al., 2014). 
Thus, the action of H2S on Cav3.2 seems to depend on ambient Zn2+, assumed to be present 
in extracellular solutions in trace amounts. Indeed, according to our atomic absorption 
spectroscopy measurements, total Zn2+ levels can reach micromolar levels in nominally 
zinc-free laboratory solutions (Huang & Gamper, unpublished); likewise, micromolar 
concentrations of Zn2+ in plasma are also reported (Moran et al., 2012). While levels of free 
Zn2+ are likely to be much lower as compared to the total zinc, it is still likely that this metal 
is present in the extracellular milieu at levels sufficient to affect channel activity. We 
hypothesize that the action of H2S results in the potentiation of channel inhibition by such 
ambient Zn2+, via a mechanism which may share commonalities with the redox modulation 
of Cav3.2 (see Abstract Figure).   
Although our data strongly suggest that H2S inhibits Cav3.2 and the endogenous T-type 
Ca2+ currents in DRG neurons, there is an alternative theory suggesting that H2S augments 
T-type Ca2+ currents, possibly by chelating Zn2+, and that this augmentation underlies the 
pro-algesic actions of this gasotransmitter (Matsunami et al., 2011;Kawabata et al., 
2007;Takahashi et al., 2010;Maeda et al., 2009). Thus, injection of the H2S-donor NaHS into 
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the rat hindpaw produced hyperalgesia which was abolished by the oxidizing agent DTNB 
(5,5'-dithiobis-(2-nitrobenzoic acid)) and by the pharmacological inhibition of T-type Ca2+ 
channels (Kawabata et al., 2007). Inhibition of endogenous H2S production also produced 
an anti-algesic effect. This and other studies by the same group led them to conclude that 
H2S could activate or “sensitize” Cav3.2 channels in order to account for its pro-algesic 
effects (Takahashi et al., 2010;Kawabata et al., 2007). Furthermore, H2S-induced colonic 
pain could be mimicked by chelation of Zn2+ (Matsunami et al., 2011). Yet, most of the 
evidence suggesting that pro-algesic effects of H2S are mediated by T-type Ca2+ channel 
augmentation is somewhat circumstantial and direct electrophysiological evidence is sparse 
and insubstantial. For example, pre-incubation of NG108-15 cells with 1.5 mM NaHS 
resulted in ~20% augmentation of endogenous T-type Ca2+ current while at 0.5mM the effect 
was not significant (Kawabata et al., 2007). Another study demonstrated that pre-incubation 
of HEK293 cells exogenously expressing Cav3.2 channels with the CSE inhibitor 
propargylglycine resulted in a reduction of the current, which was interpreted as tonic 
augmentation of recombinant Cav3.2 by endogenous H2S (Sekiguchi et al., 2014). 
Interestingly, only in the presence of this inhibitor were currents augmented by NaHS. These 
experiments are consistent with potential augmentation of T-type Ca2+ currents by H2S but 
the following has to be taken into account: i) only very high, millimolar concentrations of 
NaHS were efficacious; ii) due to the experimental protocol used (pre-incubation) these 
experiments did not directly assess the acute effect of H2S on T-type Ca2+ channel activity.  
In our hands, increasing the NaHS concentration to 3mM did augment recombinant Cav3.2 
currents, while even higher concentrations were needed to significantly augment native T-
type Ca2+ channel currents in DRG neurons (Elies et al., 2014). These experiments can, to 
some degree, reconcile conflicting experimental evidence from different laboratories and 
suggest a dual effect of H2S on T-type Ca2+ channels: H191-mediated inhibition at low 
(micromolar) concentrations and potentiation (due to an unknown mechanism) at high 
(several mM) concentrations. It is important to point out, however, that the presence H2S at 
millimolar concentrations in mammalian tissues is highly unlikely. Initial reports estimated 
plasma H2S levels within the range of 20–100 µM (Li and Moore, 2008), but even these 
values are now regarded as overestimations (Li et al., 2011). Therefore, physiologically 
relevant concentrations of H2S are unlikely to be sufficiently high to produce T-type Ca2+ 
channel augmentation. The expected effect of endogenous H2S is, therefore, inhibition of T-
type Ca2+ channel currents, at least in cells and tissues that express significant amounts of 
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Cav3.2 (such as sensory neurons). Therefore, the hypothesis that physiological levels of 
H2S can trigger pro-algesic effects via T-type Ca2+ channel activation appears questionable 
at present. Furthermore,  in our view, it is also unlikely that H2S can act as a Zn2+ chelator 
(as was suggested by (Matsunami et al., 2011) as i) chemical properties of H2S do not 
suggest metal chelating properties (e.g. the ability to form polydentate complexes); ii) acute 
application of H2S leads to T-type Ca2+ channel current inhibition, whereas Zn2+ chelation 
with TPEN causes current augmentation (Nelson et al., 2007b;Elies et al., 2014); iii) 
application of TPEN completely reverses H2S-induced T-type Ca2+ channel inhibition; iv) 
pre-application of TPEN renders H2S unable to inhibit T-type Ca2+ channels.  
At present, whilst it is hard to envisage how the painful / hyperalgesic effects of H2S 
(especially these of endogenously produced H2S) can be mediated by its effect on T-type 
Ca2+ channels, other possible targets may account for this action. Thus, H2S was suggested 
to produce some of its pro-algesic effects via TRPA1 activation (Andersson et al., 2012;Hsu 
et al., 2013). Additionally, H2S was suggested to inhibit voltage-gated K+ channels in 
trigeminal sensory neurons (most likely Kv1.1 and Kv1.4) thus producing depolarizing and 
excitatory effects (Feng et al., 2013). 
Conclusions and perspectives 
Tonic H2S production clearly impacts a variety of both physiological and pathological 
processes, and likely does so in part via direct and indirect modulation of ion channel activity. 
The numerous and diverse pathways that can be modified by H2S suggest that interventional 
control of this gasotransmitter could be therapeutically beneficial (e.g. in the cardiovascular 
system and peripheral sensory neurones). However, conflicts have arisen and must be 
resolved. We believe that at least some issues could be rectified if the experimental 
conditions through which we study the effects of H2S are standardised (e.g. preparation of 
stock solutions of H2S donors, flow rates of solutions containing donors, exposure time, and 
obligatory use of agar bridges for reference electrodes).  
Twenty years after the discovery of H2S as an endogenously bioactive molecule (Abe & 
Kimura, 1996), one of the main challenges within the field remains the measurement of 
absolute concentrations of H2S, in real time, both intracellularly and in extracellular 
compartments. For instance, development of appropriate intracellular fluorescence probes 
will expand not only the knowledge regarding intracellular concentrations of H2S in space 
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and time, but it will also help to correlate experimental data obtained from exogenously-
administered H2S with experimental data obtained from endogenously-generated H2S.  
Additionally, future research regarding the physiological effects of H2S must bear in mind 
the crosstalk signalling with other gasotransmitters (NO and CO).  Only then can we obtain 
more comprehensive and uniformly acceptable data on which to build in order to design 
modulators of H2S production and signalling for translational benefit.  
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Figure legends 
Abstract Figure 
Cartoon showing the linear structure of the transmembrane domain I of the Cav3.2 T-type 
Ca2+ channel α subunit. In the ‘tonic’ channel state (middle), zinc partially occupies a binding 
site formed by interacting residues (indicated by white dots) present in IS1-IS2 and IS3-IS4 
linkers, including H191. Under these conditions, zinc causes tonic inhibition of evoked 
currents (as illustrated by example current shown below). Chelation of zinc by TPEN (left) 
augments current amplitudes via relief of tonic zinc inhibition. In the presence of H2S, zinc 
affinity appears augmented, leading to increased zinc binding and a reduction in current 
amplitude.  
Figure 1 
Properties of T-type Ca2+ channels. (A) example currents evoked by step depolarizations 
applied (according to the protocol shown above each trace) to HEK293 cells expressing 
each of the 3 classes of T-type Ca2+ channel, as indicated. Note the relatively slow activation 
and inactivation of Cav3.3 as compared with Cav3.1 and Cav3.2. (B) Schematic current-
voltage relationship typical of T-type Ca2+ channels; note the low threshold for activation. 
(C) Superimposition of steady state inactivation plot (solid line) and activation profile (dashed 
line) typical of T-type Ca2+ channels. Note the pronounced window current (region of overlap, 
arrowed). (D) Fluorimetric recording of [Ca2+]i  in a Fura-2 loaded HEK293 cell expressing 
Cav3.2. For the period indicated by the shaded area, the T-type channel blocker mibefradil 
(1µM) was applied, causing a reduction in basal [Ca2+]i (unpublished data). (E) Cartoon of 
membrane depolarizations evoked by current injections in thalamic neurones. Note the 
evoked burst activity is almost fully suppressed in cells lacking the T-type channel Cav3.1  
(see Kim et al., 2001). 
Figure 2. 
Hydrogen sulfide synthesis and effector ion channels. Schematic illustrating the synthesis 
of H2S from homocysteine, L- and D-cysteine via enzymes shown in boxes (CBS, 
cystathionine β synthase;  CSE, cystathionine γ lyase; 3-MST, 3-mercaptopyruvate 
sulfurtransferase; CAT, cysteine aminotransferase; DAO, D-amino acid oxidase). Some of 
the target ion channels modulated by H2S are also indicated (NMDAR, N-methyl-D-
16 
 
aspartate receptor; VGCC, voltage-gated Ca2+ channel; TRP, Transient receptor potential 
channel).   
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